GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M

GeneDx Holdings Corp.

2026-Q1 EPS reported -$2.16 revenue$102,254,000

Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).
Exome/genome volume 27,488 (+34% YoY); adjusted gross margin 69% flat YoY.
GAAP net loss $63.3M; adjusted net loss $8.2M vs adjusted net income $9.2M in Q1 2025.
Full-year 2026 revenue guidance $475-$490M with at least 30% exome/genome volume growth; cash $171.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeneDx Holdings Corp. reported first quarter of 2026 results: revenue $102.3 million, net income $63.3 million.

Period: first quarter of 2026
Revenue: $102.3 million
Net income: $63.3 million
Result: reported results

Exact text from the filing

reported first quarter 2026 revenue of $102.3 million

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-26-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.